BACKGROUND: This study aimed to evaluate the safety and efficacy of weekly paclitaxel and cisplatin chemotherapy (wTP) in patients with ovarian cancer who developed carboplatin hypersensitivity reaction (HSR). METHODS: We retrospectively investigated 86 patients with ovarian, fallopian tube, and peritoneal carcinoma who developed carboplatin HSR during previous chemotherapy (carboplatin and paclitaxel) at our institution between 2011 and 2019. After premedication was administered, paclitaxel was administered over 1 h, followed by cisplatin over 1 h (paclitaxel 80 mg/m2; cisplatin 25 mg/m2; 1, 8, 15 day/4 weeks). We investigated the incidence of patients who successfully received wTP for at least one cycle, treatments compliance, progression-free survival (PFS), and overall survival (OS). RESULTS: The median number of wTP administration cycles was 4 (Interquartile Range IQR, 3-7), 71 patients (83%) successfully received wTP, and 15 patients (17%) developed cisplatin HSR. The efficacy of treatment was as follows: 55 (64%) patients completed the scheduled wTP, 9 (10%) patients discontinued due to HSR to cisplatin within 6 cycles, 1 (1%) patient discontinued due to renal toxicity (grade 2) at the 6th cycle, and 21 (24%) patients discontinued due to progressive disease within 6 cycles. The median PFS and OS after administration of wTP were 10.9 months (95% CI: 7.7-17.7) and 25.9 months (95% CI: 19.0-50.2), respectively. CONCLUSIONS: wTP was safe and well-tolerated in patients who developed carboplatin HSR.
BACKGROUND: This study aimed to evaluate the safety and efficacy of weekly paclitaxel and cisplatin chemotherapy (wTP) in patients with ovarian cancer who developed carboplatinhypersensitivity reaction (HSR). METHODS: We retrospectively investigated 86 patients with ovarian, fallopian tube, and peritoneal carcinoma who developed carboplatin HSR during previous chemotherapy (carboplatin and paclitaxel) at our institution between 2011 and 2019. After premedication was administered, paclitaxel was administered over 1 h, followed by cisplatin over 1 h (paclitaxel 80 mg/m2; cisplatin 25 mg/m2; 1, 8, 15 day/4 weeks). We investigated the incidence of patients who successfully received wTP for at least one cycle, treatments compliance, progression-free survival (PFS), and overall survival (OS). RESULTS: The median number of wTP administration cycles was 4 (Interquartile Range IQR, 3-7), 71 patients (83%) successfully received wTP, and 15 patients (17%) developed cisplatin HSR. The efficacy of treatment was as follows: 55 (64%) patients completed the scheduled wTP, 9 (10%) patients discontinued due to HSR to cisplatin within 6 cycles, 1 (1%) patient discontinued due to renal toxicity (grade 2) at the 6th cycle, and 21 (24%) patients discontinued due to progressive disease within 6 cycles. The median PFS and OS after administration of wTP were 10.9 months (95% CI: 7.7-17.7) and 25.9 months (95% CI: 19.0-50.2), respectively. CONCLUSIONS:wTP was safe and well-tolerated in patients who developed carboplatin HSR.
Authors: A Bergamini; C Pisano; M Di Napoli; L Arenare; C Della Pepa; R Tambaro; G Facchini; P Gargiulo; S Rossetti; G Mangili; S Pignata; S C Cecere Journal: Gynecol Oncol Date: 2016-10-27 Impact factor: 5.482
Authors: Robert F Ozols; Brian N Bundy; Benjamin E Greer; Jeffrey M Fowler; Daniel Clarke-Pearson; Robert A Burger; Robert S Mannel; Koen DeGeest; Ellen M Hartenbach; Rebecca Baergen Journal: J Clin Oncol Date: 2003-07-14 Impact factor: 44.544
Authors: Robert L Coleman; Nick M Spirtos; Danielle Enserro; Thomas J Herzog; Paul Sabbatini; Deborah K Armstrong; Jae-Weon Kim; Sang-Yoon Park; Byoung-Gie Kim; Joo-Hyun Nam; Keiichi Fujiwara; Joan L Walker; Ann C Casey; Angeles Alvarez Secord; Steve Rubin; John K Chan; Paul DiSilvestro; Susan A Davidson; David E Cohn; Krishnansu S Tewari; Karen Basen-Engquist; Helen Q Huang; Mark F Brady; Robert S Mannel Journal: N Engl J Med Date: 2019-11-14 Impact factor: 91.245
Authors: Jacobus Pfisterer; Catherine M Shannon; Klaus Baumann; Joern Rau; Philipp Harter; Florence Joly; Jalid Sehouli; Ulrich Canzler; Barbara Schmalfeldt; Andrew P Dean; Alexander Hein; Alain G Zeimet; Lars C Hanker; Thierry Petit; Frederik Marmé; Ahmed El-Balat; Rosalind Glasspool; Nikolaus de Gregorio; Sven Mahner; Tarek M Meniawy; Tjoung-Won Park-Simon; Marie-Ange Mouret-Reynier; Cristina Costan; Werner Meier; Alexander Reinthaller; Jeffrey C Goh; Tifenn L'Haridon; Sally Baron Hay; Stefan Kommoss; Andreas du Bois; Jean-Emmanuel Kurtz Journal: Lancet Oncol Date: 2020-04-16 Impact factor: 41.316
Authors: Andrew R Clamp; Elizabeth C James; Iain A McNeish; Andrew Dean; Jae-Weon Kim; Dearbhaile M O'Donnell; Jane Hook; Christopher Coyle; Sarah Blagden; James D Brenton; Raj Naik; Tim Perren; Sudha Sundar; Adrian D Cook; Gosala S Gopalakrishnan; Hani Gabra; Rosemary Lord; Graham Dark; Helena M Earl; Marcia Hall; Susana Banerjee; Rosalind M Glasspool; Rachel Jones; Sarah Williams; Ann Marie Swart; Sally Stenning; Mahesh Parmar; Richard Kaplan; Jonathan A Ledermann Journal: Lancet Date: 2019-11-29 Impact factor: 79.321